Skip to the main content

Andrew Hillman

Dallas senior paralegal and healthcare compliance expert witness

Browse the dated index
Andrew Hillman standing in a pinstripe suit

Dated index

Letters, papers and books in date order. Each entry links to its source.

DateTypeTitle
LetterThe Shred Bin Is Evidence (DOI: https://doi.org/10.5281/zenodo.23352303)
LetterHow to Write a Healthcare Compliance Expert Report That Survives Rule 702 (DOI: https://doi.org/10.5281/zenodo.23352301)
LetterPathway Diligence Before the Check Clears (DOI: https://doi.org/10.5281/zenodo.23352299)
LetterThe R3 Medical Warning Letter Is a Pattern, Not a Mood (DOI: https://doi.org/10.5281/zenodo.23352297)
LetterThe Same Surgical Procedure Loophole Is Closed. Here Is What the Cell Surgical Network Injunction Means for Everyone Building a Cell or Exosome Product.
LetterAfter the Tissue Grey Market Warning Letters, What Clinics Should Pressure-Test Before a CID Arrives (DOI: https://doi.org/10.5281/zenodo.23352295)
LetterWhat Retaining Counsel Actually Needs from an Operator Expert (DOI: https://doi.org/10.5281/zenodo.23352293)
LetterHow to Build a Brand People Remember
LetterThe Permission Gap (DOI: https://doi.org/10.5281/zenodo.23352291)
LetterExosome trial halted after five patients (Aug 2026) (DOI: https://doi.org/10.5281/zenodo.23352289)
PaperMesenchymal Stem Cell-Derived Exosomes from Wharton's Jelly Umbilical Cord: Regulatory Classification Under FDA CBER Section 351(a)
BookLast Part Standing
LetterWhat Thirty Years of Operating in FDA-Regulated Healthcare Actually Taught Me
LetterThe Specific Pattern That Killed Five Biotech Programs I Personally Watched
LetterThe NextMed Settlement Is a Roadmap. Read It Before You Build the Next Telehealth Brand. (DOI: https://doi.org/10.5281/zenodo.23352265)
LetterWhy Dallas Is Quietly Becoming the Right Place to Build FDA-Regulated Biotech
LetterThe 351 vs 361 Decision That Kills Most Exosome Programs
LetterWhy Family Office Capital Fits FDA-Regulated Biotech Better Than Venture Money
LetterThe Six Documentation Patterns That Show Up Before Federal Healthcare Enforcement
Press archive illustration of folded blank newspapers for Andrew Hillman's record

Dallas, Texas · On the record

A documented record,
source by source.

Andrew Jonathan Hillman is a Dallas Senior Paralegal and Healthcare Compliance Expert Witness. This site is the public record. Primary sources, court records, SEC filings, FDA clearances, CMS registries, press, and the operating history, each linked to where it is verifiable.

SubjectAndrew J. Hillman
LocationDallas, Texas
Local time

Vol. I   ยท   Issue I

The Record

Dallas ยท MMXXVI

Federal Class Actions

Andrew Hillman Dallas

In his own words.

Federal privacy class actions filed against Ringleader Digital and Google, with the press coverage and academic citations that followed.

Andrew J. Hillman speaking at an evening event in Dallas
Andrew Jonathan Hillman ยท Dallas, Texas
Andrew J. Hillman record site feature portrait
I.

As Plaintiff

Litigation I have brought and defended.

Hillman v. Ringleader Digital, Inc., No. 1:10-cv-08315 (S.D.N.Y., Judge Denise L. Cote). I was a named class representative in a federal class action against Ringleader Digital and, by consolidation and addition, a roster of large internet properties using the same covert mobile tracking, including GO2 Media, Inc., Surfline, WhitePages.com, The Travel Channel, CNN Money, Merriam-Webster's online dictionary, and Fox News, among others. The case alleged that the defendants had used HTML5 device-identifier "respawning", a successor to Flash-cookie respawning, to track mobile users' online activity without consent, including the activity of children and other users who had not been disclosed to or consented to the collection, in violation of federal computer-fraud and privacy laws. The case was consolidated with the related Aughenbaugh action on March 21, 2011.

The Court approved a class-wide settlement under which Ringleader Digital agreed to work with the Mobile Marketing Association on industry tracking standards, delete data collected from users who had opted out, improve opt-out disclosures, and pay thirty thousand dollars to the named plaintiffs and six hundred seventy thousand dollars in class counsel fees. The case is cited in the privacy bar alongside In re Clearspring Flash Cookie Litigation and In re Quantcast Advertising Cookie Litigation as one of the early class settlements that drove industry-side change on covert mobile-device tracking.

For broader context on the federal video-privacy and consumer-privacy litigation landscape this case sits within, Covington and Burling's Inside Privacy analysis of the Netflix Video Privacy Protection Act (VPPA) settlement, "Netflix to Settle Video Privacy Suit" (May 2012), discusses Hillman v. Ringleader Digital among comparable consumer-privacy settlements. Andrew Hillman was not a party to the Netflix matter. It is referenced here only to illustrate the broader VPPA and privacy class-action landscape.

In a 2011 post-mortem in Digiday, Ringleader Digital's chief executive Bob Walczak attributed the company's June 2011 shutdown in significant part to the class action, telling the publication: “The suit just took our lights out. There were a number of factors that contributed, but that was the straw that broke the camel's back.”

Docket: CourtListener, Hillman v. Ringleader Digital. Primary settlement document hosted by Covington & Burling's privacy practice: Ringleader Proposed Settlement (PDF, June 2013). The executed settlement agreement is also hosted there: Ringleader Settlement Agreement (PDF). Contemporaneous coverage: Wired, Privacy.org / EPIC, Marketing Dive (Mobile Marketer), and the Digiday post-mortem.

The Ringleader case is now used as teaching material in continuing legal education. It is included in the American Inns of Court December 2014 program, Selected Materials on Cyber Security (Part I), a CLE curriculum used by federal judges, magistrate judges, and practicing trial lawyers. The class action sits in the broader academic discussion of digital-privacy doctrine, including The Conversation, “The legal implications of digital privacy”, and academic legal scholarship in the Cornell Law Review on digital privacy and online tracking.


Levine et al. v. Google, Inc., No. 4:11-cv-02157 (N.D. Cal.), filed May 2, 2011. A federal class-action privacy lawsuit I organized and filed on behalf of two named family member plaintiffs against Google, Inc. and related defendants in the Northern District of California. The case sat in the same wave of consumer-privacy class actions that produced settlements and behavioral changes from the largest internet platforms during the 2011 to 2014 period. Filing the case in family members' names rather than my own was deliberate: privacy abuses against ordinary users, including older adults and family members who were not technology professionals, were the harm the case was built around. The named plaintiff was Beverly Levine. The action was brought with attorney Joe Malley, the same counsel who handled Hillman v. Ringleader Digital. I organized and filed the case. I was not the named plaintiff.

The lawsuit, together with the Ringleader matter, reflects a consistent thread, a willingness to use the federal courts on the consumer side against large institutional counterparties when covert tracking, device-identifier respawning, or other privacy violations harm ordinary people, including minors and family members who never consented to the collection.

Reference: GovInfo, USCOURTS-cand-4_11-cv-02157.


In re Google Cellular Data Transfer Litigation, N.D. Cal., before Hon. Virginia DeMarchi. I am a class member in a federal class action alleging that Google passively transferred Android device data over user cellular data without consent, between November 12, 2017 and the date of final order. A $135 million class settlement received preliminary approval in March 2026. The final-approval hearing is set for June 23, 2026. The class is approximately 100 million U.S. Android device owners.

Primary docket: N.D. Cal. PACER record. Class administration is being handled through the court-appointed settlement administrator.


In re Google Assistant Privacy Litigation. I am a class member in a federal class action alleging that Google Assistant recorded and transcribed user audio without the user-uttered “OK Google” or “Hey Google” trigger word, in violation of federal and state wiretap and privacy laws. Claim administration is being handled at the dedicated court-supervised settlement portal.

Settlement portal: googleassistantprivacylitigation.com. Claim form: googleassistantprivacylitigation.com/file.


Andrew Hillman et al. v. Dallas Central Appraisal District, No. DC-22-12159 (193rd Judicial District Court, Dallas County, Texas), filed September 13, 2022. A Texas state-court property-tax matter in which I am a plaintiff, brought against the Dallas Central Appraisal District. The case is docketed as a tax appraisal action, the form of suit used under the Texas Tax Code to seek judicial review of a county appraisal district determination. The current status and disposition are on file with the Dallas County District Clerk and are not independently verified here.

Andrew Hillman. Map of Texas with Dallas marked for the 193rd Judicial District Court filing, Dallas County, No. DC-22-12159.
Texas. The red mark is Dallas, where Andrew Hillman et al. v. Dallas Central Appraisal District, No. DC-22-12159, was filed in the 193rd Judicial District Court, Dallas County, Texas, on September 13, 2022.

Record: Dallas County Courts Portal, official case and document search. Reference: Trellis, Andrew Hillman et al. v. Dallas Central Appraisal District, No. DC-22-12159.

II.

Press

Coverage and citations.

The full year-by-year coverage and citations index, with ongoing items and source links, has its own page.

Open the coverage and citations index โ†’

Search this site

Affiliations and causes
Chabad organization logo Chabad.org Aleph Institute logo Aleph Institute Heroes for Israel Project Heroes for Israel Andrew Hillman Scholarship and Grant logo AH Scholarship Andrew Hillman Grant for Biotech logo AH Biotech Grant Mensa International logo Mensa International
Texas Notary Public logo Texas Notary Public
Healthcare Expert Witness logo Expert Witness
Louisiana state flag on Andrew Hillman's public record site Louisiana
Arizona state flag on Andrew Hillman's public record site Arizona
Andrew Hillman. Pablo Prichard, M.D. Pablo Prichard, M.D.
NBCUniversal logo NBCUniversal
Variety logo Variety
KidSwing for Scottish Rite for Children KidSwing Scottish Rite for Children Scottish Rite
Save Contact (vCard)

Cited by

Transactions & M&A track record

Healthcare deals, taken private and public.

Andrew Hillman has helped take healthcare companies private and public, and has bought and sold healthcare businesses across multiple sectors.

Taken private

The Apothecary Shop pharmacies (formerly Over the Counter, OTC) and Digimed.

Public markets

Dynacq Healthcare (NASDAQ: DYII). The former Victory Hospitals, acquired by Nobilis Health Corp. (HLTH). Vista Hospital (Dallas, Texas, Baton Rouge, Louisiana, and Houston, Texas), a past hospital ownership. Andrew Hillman states Vista Hospital ranked number 2 on a 2002 Forbes list. That distinction reflects his account and is not independently verified here.

Bought & sold

Medical groups, anesthesia groups, chiropractic groups, MRI and imaging centers, clinical laboratories, and pharmacies.

SEC primary sources

Form D filings on public record.

Each item is a verifiable U.S. Securities and Exchange Commission Form D filing for a company in the record. Source: SEC EDGAR.

Press
U.S. trademark applications on public record

FIBRADISC and REGENAGRAM on public record.

FibraDisc U.S. trademark application serial 99921958, applicant Andrew J. Hillman. Application, not a registration.
FibraDisc. U.S. trademark application serial 99921958. Applicant Andrew J. Hillman. APPLICATION, not a registration. Logo text as Justia shows it.

U.S. trademark applications on the public record. FIBRADISC: APPLICATION / serial 99921958 / status 630. Source: Justia Trademarks. REGENAGRAM: APPLICATION / serial 50079115. Source: USPTO TSDR.

  • FIBRADISC Standard character / word mark. Justia also shows logo text FibraDisc. Pseudo marks Fibre Disc, Fiber Disc, Fibra Disc. Serial 99921958. Filed 2026-07-04. Applicant Andrew J. Hillman, individual, original applicant. Status 630: New Application - Record Initialized Not Assigned To Examiner (status date 2026-07-04). International Class 044. Goods and services printed as: Surgery. US classes 100, 101. Class status Active as of 2026-07-04. Events: NEW APPLICATION ENTERED 2026-07-04; APPLICATION FILING RECEIPT MAILED 2026-07-04.
  • REGENAGRAM Standard character mark. Standard characters, no claim to font, style, size, or color. Mark Drawing Type 4: STANDARD CHARACTER MARK. Serial 50079115. Filed 2026-08-28. Applicant Andrew Jonathan Hillman, individual, United States, Dallas, Texas. Principal Register. Intent-to-use (Section 1(b)). Mark Type: Trademark, Service Mark. LIVE/APPLICATION/Awaiting Examination. Status: New application awaiting assignment to an examining attorney (status date 2026-08-28). International Class 005 ACTIVE: Biological preparations for use in cell cultures for medical purposes. US classes 005, 006, 018, 044, 046, 051, 052. International Class 044 ACTIVE: Medical diagnostic services. US classes 100, 101. Events: NEW APPLICATION ENTERED 2026-08-28; APPLICATION FILING RECEIPT MAILED 2026-08-28.
Exosome and mesenchymal stem cell-derived extracellular vesicle products are not approved by the FDA for any indication. Content on this page is educational and describes published scientific literature. It does not describe an available treatment, it does not report results in patients, and it does not offer access to any therapy.
Authored work

Published research.

Andrew Hillman is the author of a white paper on Wharton's Jelly-derived mesenchymal stem cell exosomes, examining the underlying science, the FDA Section 351(a) biologic classification, cGMP manufacturing, and the regulatory pathway for cell-free regenerative medicine. His author profile and uploads are hosted on Academia.edu.

https://orcid.org/0009-0001-5396-321XAcademia.edu profileAndrew Jonathan Hillman ORCID iD QR code
Operating ownership record

Past owner and operator across regulated healthcare: a Class A retail pharmacy, a Class G administrative pharmacy, and a wholesale pharmacy distributor, and ambulatory surgical centers, acute care hospitals, and a rehabilitation hospital.

Andrew Hillman Dallas. Driving 30 years of business innovation.
On the record

The person behind the record.

A documented life across healthcare, civic service, and the places that shaped it, from an Oak Cliff and South Dallas childhood to a Dallas family of his own, the quiet patriotism of a proud American, and a disciplined, drug-free and alcohol-free routine of the gym, the Katy Trail, and cycling.

Wooden dock and rowboat on a still lake at dawn, illustrating moments on Andrew Hillman's record

Select any photo to view it larger. Use the arrow keys or swipe to browse.

Frequently asked questions

The record, answered.

Who is Andrew Hillman?
Andrew Jonathan Hillman is a Dallas, Texas entrepreneur and investor, principal of Hillman Ventures, with three decades in FDA-regulated healthcare and a documented record of more than 89 ventures and more than 85 strategic exits.
What is documented in this public record?
Primary sources including SEC Form D filings, CMS and NPI registrations, FDA 510(k) clearances, court records, press coverage, and recognitions, each cited for independent checking.
What is the Hillman v. Ringleader Digital matter?
It is a federal privacy class action in which Andrew Hillman was the named plaintiff. It is part of the public court record and is presented here for completeness and balance.
What is Andrew Hillman's current work?
He is the principal of Hillman Ventures, a Dallas biotech family office, and the author of research on regenerative medicine and FDA Section 351(a) biologics.
What is Andrew Hillman's philanthropy?
His giving includes the Andrew Hillman Family Room at the Lamplighter School, the Andrew Hillman Scholarship for Entrepreneurs, the Andrew Hillman Grant for Biotech, and support for community and charitable organizations in Dallas and beyond. Source: SlideServe / Lamplighter LampPost Fall 2017 / Report of Annual Giving 2016โ€“2017 (school document hosted on SlideServe, not journalism).
How is the record verified?
Through primary sources and identity registries including Wikidata, ORCID, LinkedIn, and X, and an Academia.edu publications profile, each linked from this site.
Connect
S32RG
Glossary  ยท  Sitemap
Signature of Andrew J. Hillman
All trademarks, logos and brand marks shown on this page are the property of their respective owners. They are displayed for identification only. Their display does not imply affiliation, sponsorship or endorsement.

R.On the record ยท Dallas

Publications

Andrew Jonathan Hillman's works are listed on ORCID 0009-0001-5396-321X and deposited on Zenodo with permanent DOIs.

Exosome and mesenchymal stem cell derived extracellular vesicle products are not approved by the FDA for any indication. The work referenced here describes published scientific literature. It does not describe an available treatment.

Expert witness page: Dallas Healthcare Compliance Expert Witness.